All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2017-06-16.
From the record
Tandem Diabetes Care, Inc.'s filings since 2017 show 1 warning event: a notice about its exchange listing (8-K item 3.01, the latest 2017-06-16) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+31.9% a year over 10 filed years; profitable in 1 of 10.
From the record
Tandem Diabetes Care, Inc.'s 10 filed years say what it did: revenue went from $84 million in fiscal 2016 to $1.0 billion in fiscal 2025, up 31.9% a year; it rose in 8 of 9 years; the deepest fall was 7% from fiscal 2022 to fiscal 2023; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 6.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Tandem Diabetes Care, Inc.'s shareholder treatment is put at 6.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 32% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -132%: lost 132¢ per shareholder dollar. Leverage 82%: owes 82¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Tandem Diabetes Care, Inc. lost about 132 cents for every dollar of shareholders' money, and gross profitability: its products earned about 62 cents per dollar of everything the company owns. Leverage: it owed about 82 cents per dollar of assets, and net share issuance: its share count grew 2.8% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 43% of 109 in its family; net margin -20.2%.
From the record
Tandem Diabetes Care, Inc.'s standing among 109 graded names in its industry family: revenue of $1.0 billion in fiscal 2025 ranks in the top 19% by size; a net margin of -20.2% ranks in the top 48%; revenue growth of 8.2% a year over the last 3 filed years ranks in the bottom 38% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 38% of 91 in its family for leadership; chief executive since 2019.
From the record
Tandem Diabetes Care, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Sheridan, John F (PRESIDENT & CEO, as filed), filing under that title since 2019-05-17, 7.5 years (top 32% of its family); the 17 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 45%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 17 people in charge now (top 36%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 40% of 104 in its family for room to expand.
From the record
Tandem Diabetes Care, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $91 million against debt of $310 million leaves -24.9% of its assets as net cash, bottom 11% of its family; cash from operations less capital spending is -2.9% of revenue (top 46%); a gross margin of 53.8% (bottom 35%); research spending of 19% of revenue (top 40%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 36% of 105 in its family for growth drivers.
From the record
Tandem Diabetes Care, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 8.2% a year over the last three filed years against 31.9% over all 10, slowing (bottom 11% of its family); the newest year grew 7.9% (bottom 34%); research spending grew 11.6% a year (top 33%); capital spending grew -16.4% a year (bottom 33%) (its annual reports). Tandem Diabetes Care, Inc. reported 2 product lines in fiscal 2025: Supplies and Other at $551 million (54%), Pump at $464 million (46%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
bottom 32% of 88 in its family for expectations against reality.
From the record
Tandem Diabetes Care, Inc.'s newest year against its own record: revenue of $1.0 billion in fiscal 2025 came in 0.4% below the $1.0 billion its prior three years' pace pointed to (top 40% of its family); net income of $205 million against a prior three-year average of $138 million (bottom 16%); a net margin of -20.2% against -17.3% before (bottom 20%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made